UNSPSC 51286301: Picloxydine

This classification denotes a topical anti-infective agent with the molecular formula C20H24Cl2N10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4YC2PY3AEU, chemically known as 1,1-(1,4-piperazinediylbis(imidocarbonyl))bis(3-(p-chlorophenyl)guanidine) but more generally known as picloxydine, which bears US NIH Compound Identifier 5748610. European Medicines Agency schedules Picloxydine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09813MIG.

UNSPSC 51286301 Picloxydine, a Commodity code, encompasses pharmaceutical products that state and local health agencies and county health systems procure for community health, emergency preparedness, and public health response programs. The code's recent activity reflects acquisition of specific pharmaceutical agents—antimicrobials, overdose-reversal medications, and related medical supplies—through both piggyback consortium arrangements and direct competitive bidding. State and local health departments, county public health offices, and county community health systems drive demand under this code, typically issuing solicitations through established cooperative purchasing vehicles or county e-procurement portals.

Illinois Department of Public Health awarded a piggyback pharmaceutical contract through the MMCAP Infuse consortium to Chartwell Rx LLC in August 2026 for supply of Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg tablets, with the contract valued at $2,999,999.11 over 12 months plus two optional renewal years. Seminole County, Florida, issued an IFB in June 2026 for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford and a two-year initial term plus one-year renewal option. Recent activity concentrates in Florida and Illinois; geographic spread beyond these states is not evident in the available opportunities. Both procurements required vendors to meet standard compliance certifications including drug-free workplace and E-Verify confirmation, with no explicit set-asides or disadvantaged-enterprise designations noted.